Abstract:G protein-coupled receptors (GPCRs) constitute a superfamily of membrane proteins which have in common the presence of 7 transmembrane α-helices linked by several intra- and extracellular loops. This particular structure is important for extracellular stimulus recognition through the amino acids forming the extracellular loops (class B, C and F of GPCRs) or by the transmembrane α-helices (class A and B of GPCRs). Their structure is also essential for signal transduction via intracellular proteins (G proteins, arrestins and kinases – GRKs-) [ Citation 1 ]. These proteins are attached to the intracellular loops and/or to the intracellular regions of the α-helices of the GPCRs, even when they are not activated by extracellular ligands or drugs. When GPCRs are activated, there is a modification of their protein structure that allosterically transmits the signal from the binding pocket to those intracellular effector proteins [ Citation 2 , Citation 3 ]. Importantly, GPCRs participate in more than 80% of the signal transduction processes that occur across plasma membrane. As more than 800 GPCRs have been identified in the human genome, this superfamily of receptors constitutes the largest protein superfamily codified in our genome. Most of these receptors are activated by sensory stimuli, mainly smell, and around 360 are stimulated by extrasensorial ligands, from small molecules to large proteins. Furthermore, more than 90% of GPCRs are expressed in the CNS and, thereby, are involved in the vast majority of neuronal functions [ Citation 4 ]. Their protein structure alteration by polymorphisms, mutations and posttranslational modifications, among others, can affect their ability to be activated by extracellular signals and/or their capacity to transduce these signals intracellularly. Therefore, structural alterations have been associated with many pathologies, including degenerative, neurological, inflammatory and cancerous [ Citation 5 ]. Moreover, alterations in protein structure can be associated with a decrease in drug therapeutic efficacy and with the appearance of patient-related side effects [ Citation 6 ]. Given the aforementioned, currently, GPCRs constitute the most important superfamily of membrane proteins pharmacologicaly targeted in clinical practice. Interestingly, among all the drugs approved by the Food and Drug Administration (FDA), around 35% target GPCRs [ Citation 7 , Citation 8 ]. Until 2017, the FDA and the European Medicines Agency (EMA) had approved 475–704 drugs for 108–134 different GPCRs, mainly aminergic and opioid receptors (e.g. cariprazine, brexpiprazole, naloxegol, or naldemedine) [ Citation 7 , Citation 8 ]. Moreover, there are 321 drugs targeting GPCRs in clinical trials (e.g. LJPC-501, INT-767, or RX-10045), 66 of which acting on GPCRs that are not currently a target of any approved drug [ Citation 7 ]. Between 2011 and 2015 the sales of drugs acting on GPCRs amounted to 917 billion USD [ Citation 9 ]. The development of such a great number of dugs has been achieved applying classical and modern techniques and methodologies along with in-silico and experimental approaches or a combination of both. These drugs activate, block or modulate (increasing or decreasing) the function of GPCRs targeting their orthosteric or allosteric centers (see section 4). In 2017, Gloriam and collaborators [ Citation 7 ] published a study about drugs acting on GPCRs approved or in clinical trials. These authors pointed out that there is a tendency to search for drugs more selective than classical drugs that usually have a polypharmacology with an average of 4–10 possible targets. They also state that aproximately 56% of non-sensory GPCRs are clinically unexplored. Among them, a substantial proportion (27%) are orphan GPCRs, which are receptors lacking known endogenous ligands. Therefore, the study of function and pharmacology of orphan GPCRs could potentially unravel new targets for the treatment of numerous pathologies. In fact, several drugs targeting orphan GPCRs are in clinical trials (e.g. G -Abstract Truncated-

Pharmacological Development of G Protein-Coupled Receptors Allosteric Modulation

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.

G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery

The Progress of Pharmacology of GABAB Receptors Allosteric Modulators

Pharmacologically Targeting Intracellular Allosteric Sites of GPCRs for Drug Discovery.

Allosteric Modulation of Ligand-gated Ion Channel Receptor

Allosteric Sites and Allosteric Regulators of G Protein-Coupled Receptors: Gray Cardinals of Signal Transduction

Protein Allostery in Drug Discovery

Design of allosteric modulators that change GPCR G protein subtype selectivity

Activation Pathway of a G Protein-Coupled Receptor Uncovers Conformational Intermediates As Targets for Allosteric Drug Design

Structure, function and drug discovery of GPCR signaling

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

Design of multivalent ligand targeting G-protein-coupled receptors.

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

What are the current trends in G protein-coupled receptor targeted drug discovery?

Discovery of GPCR ligands for probing signal transduction pathways

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs

GPCRs involved in metabolic diseases: pharmacotherapeutic development updates

Are GPCRs Still a Source of New Targets?

Positive allosteric modulation of a GPCR ternary complex